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Abstract
We performed analytical validation of the new version
of the Liaison N-Tact PTH (parathormone) assay
according to NCCLS guidelines and compared this
new generation of reagent with the Roche Elecsys
PTH assay. We showed that this new version is a sen-
sitive and precise method with good recovery. Sig-
nificant carryover was observed, but with limited
clinical implications. We demonstrated that the new
version of the Liaison PTH is in reasonably good
agreement with the Roche Elecsys PTH assay, and as
we observed no differences in a hemodialyzed pop-
ulation, moving from one method to the other should
not affect the daily follow-up of patients. However,
one should be cautious with the highest values
()500 pg/mL). We established reference intervals of
12–54 pg/mL for the Liaison and 14–52 pg/mL for the
Elecsys assay.
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Parathormone (PTH), an 84-aa polypeptide hormone
synthesized and secreted by the parathyroid glands,
is a major regulator of bone metabolism and calcium
homeostasis. PTH determination is frequently pre-
scribed in clinical routine to manage renal osteodys-
trophy in patients with chronic kidney disease (CKD)
or in patients with disorders of mineral metabolism.
The objective of this investigation was to evaluate the
analytical performance of the new version of Liaison
N-Tact PTH assay (DiaSorin, Saluggia, Italy) according
to the NCCLS guidelines (1). We also compared this
new generation of reagent with the Roche Elecsys
PTH assay (Roche Diagnostics, Mannheim, Germany)
and established reference intervals for the two kits.
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The study was performed using blood samples col-
lected in serum gel separators with a clot activator
(Terumo, Haasrode, Belgium).
The Liaison N-Tact PTH assay is a chemilumines-
cence immunoassay (CLIA) using a first antibody
directed against the N-terminal (aa 1–34) region of the
molecule conjugated to an isoluminol derivative and
a second antibody directed against the C-terminal (aa
39–84) region immobilized on magnetic particles.
During incubation, PTH binds to the solid phase and
is subsequently bound by isoluminol-conjugated anti-
body. After incubation, the unbound material is
removed with a wash cycle. The starter reagent
is then added and a flash chemiluminescent reaction
is initiated. The light signal is measured by a photo-
multiplier as relative light units (RLU) and is propor-
tional to the concentration of PTH present in the
samples.
The Roche intact PTH assay is an electrochemilu-
minescence method based on a sandwich reaction:
one biotinylated monoclonal anti-PTH antibody is
directed against the N-terminal (aa 26–32) portion of
the molecule (2) and a second monoclonal antibody,
labeled with ruthenium, recognizes the C-terminal
fragment (aa 38–84). The inter-assay precision on an
Elecsys 1010 platform is -5% at both 46 and 341
pg/mL.
We assessed the intra- and inter-assay precision at
two levels (41 and 129 pg/mL) using 15 determina-
tions per level, as well as the functional sensitivity
(defined as the lowest PTH concentration giving a CV
-20% in an inter-assay determination). Intra- and
inter-assay CVs were -10% and the functional sen-
sitivity was found to be 12 pg/mL.
Recovery was determined according to NCCLS
guideline EP-6P: five low-concentration serum sam-
ples and five high-concentration samples were as-
sayed a minimum of five times to establish levels in
neat serum. These samples were then mixed at ratios
of 1:3, 1:1 and 3:1 and re-assayed in replicates of
three. The results are excellent, as listed in Table 1.
We diluted two patient samples (1348 and 1220
pg/mL) 1:2, 1:4, 1:8, 1:16, 1:32, 1:64 and 1:128 with
0.05 M phosphate buffer (pH 7.5) containing 0.9%
NaCl. The results were then plotted and the expected
vs. observed values analyzed by least-squares linear
regression. The dilutions resulted in a linear plot
(Figure 1) and the regression equation was: meas-
ureds0.9951(expected)q6.0, with a correlation coeff-
icient of 0.99.
We spiked four patient samples of previously deter-
mined PTH concentrations with human PTH 1–84
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3L:1H 119 129 108
1L:1H 232 245 106




3L:1H 31 26 84
1L:1H 57 48 84
1L:3H 84 70 83
Sample 3 18
Low neat 219
High neat 69 70
3L:1H 119 98 102
1L:1H 169 181 83
1L:3H 107
Figure 1 Dilution linearity of the Liaison PTH assay.
Least-square linear regression of the measured vs. expected
values is ys0.9951xq6.0 (rs0.99).
Figure 2 Bland-Altman plot for PTH obtained in 185 patients
with the Liaison second-generation PTH and Roche Elecsys
PTH assays.
Results are given in pg/mL.
(Bachem, Bubendorf, Switzerland) at concentrations
of 6, 13, 33 and 65 pg/mL. The mean recovery was
95% (range 87–101%).
To assess the hook effect, we spiked PTH 1–84
(Bachem) into patient samples at levels of 783,000
–7.8 pg/mL in six-fold steps. Raw relative light unit
(RLU; background normalized light output) readings
were used, as the instrument does not report concen-
trations )2000 pg/mL. The raw RLU response to
spiked PTH was linear between 250 and 6300 pg/mL,
as judged by -10% deviation from predicted results
based on extrapolation of the calibration curve. At
concentrations )6300 pg/mL, the response curve flat-
tened. A hook was observed for a spiked concentra-
tion of 783,000 pg/mL.
We evaluated possible carryover by placing four
consecutive blank samples after a patient sample con-
taining a high level of PTH (1273 pg/mL); the first
blank sample was measured at a significant level of
6 pg/mL, while the other samples were considered as
negative (-2.5 pg/mL).
We generated fasting reference intervals for the
Liaison PTH and Roche Elecsys PTH assays using 60
patients (11 male, 49 female) aged 23–85 years with
25-OH vitamin D levels )50 nmol/L, glomerular filtra-
tion rate evaluated by the MDRD (3) formula )60
mL/min/1.73 m2, negative rheumatoid factor (RF) and
total calcium level within the laboratory reference
range. The reference interval was determined to be
12–54 pg/mL for the Liaison and 14–52 pg/mL for the
Roche Elecsys assay. We found no age- or gender-
related differences.
We compared the Liaison second-generationN-Tact
PTH assay with another chemiluminescent method,
the Roche Elecsys PTH, using 185 consecutive non-
hemodialyzed patients with PTH levels of 12–208
pg/mL. Data were analyzed by Passing-Bablok regres-
sion and Bland-Altman plots. The Liaison assay
showed good agreement with the Elecsys method
(rs0.93, CI 0.91–0.95; slope 1.16, CI 1.12–1.21; inter-
cept –4, CI –6 to –2). The Bland-Altman plot showed
a mean difference of –4.3 pg/mL and an inflexion
point near the upper reference interval (54 pg/mL),
with a trend for Liaison to read higher than Elecsys at
high concentrations and lower at low concentrations
(Figure 2). The Wilcoxon test showed no differences
between the Liaison and Elecsys assays in patients
with normal PTH (28 vs. 27 pg/mL, ns96), but in
patients with PTH )54 pg/mL, the Liaison results
were significantly higher than the Elecsys results (81
vs. 71 pg/mL, ns89, p-0.0001).
We also compared the two methods in 71 hemo-
dialyzed patients with PTH levels ranging from 15 to
824 pg/mL. In this population, no difference was ob-
served between the median values (Elecsys 276
pg/mL and Liaison 289 pg/mL, p)0.05). The Bland-
Altman plot showed a mean difference of 39 pg/mL,
but a discrepancy was observed in the results for the
three patients presenting the highest PTH levels (Liai-
son results 685, 627 and 694 pg/mL, Elecsys results
1269, 1306 and 1313 pg/mL, respectively) (Figure 3).
However, the results were in good agreement (slope
0.89, CI 0.89–0.99; intercept –11.4, CI –1.7 to –22.6),
with rs0.89 (0.83–0.93).
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Figure 3 Bland-Altman plot for PTH obtained in 71 hemo-
dialyzed patients with the Liaison second-generation PTH
and Roche Elecsys PTH assays.
Results are given in pg/mL.
In conclusion, our data indicate that the Liaison sec-
ond-generation PTH assay is a sensitive and precise
method. The recovery is good and we observed sig-
nificant carryover, albeit with limited clinical implica-
tions. We demonstrated that the Liaison second-
generation PTH assay is in reasonably good agree-
ment with the Roche Elecsys PTH assay, but in
patients with elevated serum PTH, the Liaison results
are higher than the Elecsys results.
It has recently been shown (4) that inter-method
variability in PTH measurement can lead to opposite
therapeutic decisions in an individual patient, depend-
ing on the PTH assay used. Adaptations (5, 6) of the
K/DOQI guidelines (7) have been suggested, as these
recommendations are based on a determination of
PTH by the Nichols Allegro PTH assay. As we did not
observe any differences in our hemodialyzed popu-
lation for PTH measured by the Elecsys and Liaison
second-generation assays, moving from one method
to the other should not affect the daily follow-up of
patients. However, caution is required for the highest
values ()500 pg/mL). Indeed, in our limited popula-
tion, the Roche Elecsys PTH assay seemed to over-
estimate these results compared to the Liaison assay
and the N-Tact PTH SP IRMA (DiaSorin) (data not
shown). We have no clear explanation for the dis-
crepancies observed in these patients. This issue
should be studied in a larger sample of hemodialyzed
patients with severe hyperparathyroidism.
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